No Data
With 64% Institutional Ownership, Regulus Therapeutics Inc. (NASDAQ:RGLS) Is a Favorite Amongst the Big Guns
JonesTrading Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $8
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences
Oppenheimer Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $7
Regulus Therapeutics Poised for Growth: Promising ADPKD Study Results and Strategic Milestones Drive Buy Rating
Buy Rating for Regulus Therapeutics Driven by Promising Clinical and Regulatory Prospects for RGLS8429
No Data
